These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31423903)

  • 1. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
    Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
    Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
    Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
    N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
    Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
    Forman M; Palcza J; Tseng J; Stone JA; Walker B; Swearingen D; Troyer MD; Dockendorf MF
    Clin Transl Sci; 2019 Sep; 12(5):545-555. PubMed ID: 31215755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
    Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
    Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
    Chris Min K; Dockendorf MF; Palcza J; Tseng J; Ma L; Stone JA; Kleijn HJ; Hodsman P; Masuo K; Tanen M; Troyer MD; van Vugt M; Forman MS
    Clin Pharmacol Ther; 2019 May; 105(5):1234-1243. PubMed ID: 30347431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of intermolecular interactions and stability of verubecestat in the active site of BACE1: Development of first model from QM/MM-based charge density and MD analysis.
    Saravanan K; Sivanandam M; Hunday G; Mathiyalagan L; Kumaradhas P
    J Biomol Struct Dyn; 2019 Jun; 37(9):2339-2354. PubMed ID: 30044206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.
    Querol-Vilaseca M; Sirisi S; Molina-Porcel L; Molina B; Pegueroles J; Ferrer-Raventós P; Nuñez-Llaves R; Dols-Icardo O; Balasa M; Iulita MF; Blesa R; Belbin O; Clarimon J; Fortea J; Gelpi E; Sánchez-Valle R; Lleó A
    Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12781. PubMed ID: 34825396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy.
    Sergott RC; Raji A; Kost J; Sur C; Jackson S; Locco A; Patel A; Furtek C; Mattson B; Egan MF
    J Alzheimers Dis; 2021; 79(1):275-287. PubMed ID: 33252075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Merck ends trial of potential Alzheimer's drug verubecestat.
    Hawkes N
    BMJ; 2017 Feb; 356():j845. PubMed ID: 28202490
    [No Abstract]   [Full Text] [Related]  

  • 15. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.
    Scott JD; Li SW; Brunskill AP; Chen X; Cox K; Cumming JN; Forman M; Gilbert EJ; Hodgson RA; Hyde LA; Jiang Q; Iserloh U; Kazakevich I; Kuvelkar R; Mei H; Meredith J; Misiaszek J; Orth P; Rossiter LM; Slater M; Stone J; Strickland CO; Voigt JH; Wang G; Wang H; Wu Y; Greenlee WJ; Parker EM; Kennedy ME; Stamford AW
    J Med Chem; 2016 Dec; 59(23):10435-10450. PubMed ID: 27933948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
    Wessels AM; Lines C; Stern RA; Kost J; Voss T; Mozley LH; Furtek C; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; Dupre N; Randolph C; Michelson D; Andersen SW; Shering C; Sims JR; Egan MF
    Alzheimers Dement; 2020 Nov; 16(11):1483-1492. PubMed ID: 33049114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.
    Thaisrivongs DA; Miller SP; Molinaro C; Chen Q; Song ZJ; Tan L; Chen L; Chen W; Lekhal A; Pulicare SK; Xu Y
    Org Lett; 2016 Nov; 18(22):5780-5783. PubMed ID: 27934506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions.
    Voss T; Kost J; Mercer SP; Furtek C; Randolph C; Lines C; Egan MF; Cummings JL
    J Alzheimers Dis; 2023; 92(1):341-348. PubMed ID: 36744336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
    Imbimbo BP; Watling M
    Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
    [No Abstract]   [Full Text] [Related]  

  • 20. Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.
    Evin G
    BioDrugs; 2016 Jun; 30(3):173-94. PubMed ID: 27023706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.